Fulcrum Therapeutics (FULC) Cash from Operations: 2019-2025
Historic Cash from Operations for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to -$14.2 million.
- Fulcrum Therapeutics' Cash from Operations rose 25.60% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.0 million, marking a year-over-year decrease of 596.78%. This contributed to the annual value of -$2.2 million for FY2024, which is 97.56% up from last year.
- Latest data reveals that Fulcrum Therapeutics reported Cash from Operations of -$14.2 million as of Q3 2025, which was down 2.68% from -$13.8 million recorded in Q2 2025.
- Over the past 5 years, Fulcrum Therapeutics' Cash from Operations peaked at $58.9 million during Q2 2024, and registered a low of -$27.9 million during Q3 2022.
- Its 3-year average for Cash from Operations is -$12.4 million, with a median of -$19.1 million in 2024.
- In the last 5 years, Fulcrum Therapeutics' Cash from Operations crashed by 401.18% in 2021 and then skyrocketed by 383.37% in 2024.
- Over the past 5 years, Fulcrum Therapeutics' Cash from Operations (Quarterly) stood at -$21.9 million in 2021, then rose by 9.89% to -$19.7 million in 2022, then decreased by 17.58% to -$23.2 million in 2023, then climbed by 27.62% to -$16.8 million in 2024, then increased by 25.60% to -$14.2 million in 2025.
- Its last three reported values are -$14.2 million in Q3 2025, -$13.8 million for Q2 2025, and -$15.3 million during Q1 2025.